CRISPR Therapeutics develops gene-based medicines using CRISPR/Cas9 editing, co-founded on foundational work by Emmanuelle Charpentier. Its lead therapy for sickle cell disease emerged from research partnerships spanning ETH Zurich and leading hematology centers.
R&D SPEND
$0.7B
INDUSTRY
Biotech120
ACADEMIC COLLABORATIONS
900
PATENTS
TRY IT
Researchers connected to CRISPR Therapeutics
Install the CLI and run your first search in under a minute. No account required to explore.
npx sci-buy@latest COPIED